$HALB Halberd Pre-Clinical Test Protocol Approved
Post# of 630
(Total Views: 195)
Posted On: 05/09/2023 8:30:16 AM
$HALB Halberd Pre-Clinical Test Protocol Approved
https://www.accesswire.com/753622/Halberd-Pre...l-Approved
Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month's End
JACKSON CENTER, PA / ACCESSWIRE / May 9, 2023 / Halberd Corporation (OTC PINK:HALB) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered. Parameter quantification and preliminary data gathering will begin as early as next week.
Medical literature indicates that a pathophysiologic connection exists between various excess neurotransmitters and certain neurodegenerative diseases. Halberd's study aims to establish positive outcomes through limiting the presence of excess neurotransmitters through its patent-pending triple-action nasal spray containing ingredients to prevent inflammation and swelling, inhibit generation of excess excitatory neurotransmitters, and decrease hypermetabolism.
This nasal spray technology represents an expansion of Halberd's extracorporeal methodology in treating medical conditions through a preventative approach and provides additional intellectual property opportunities, an avenue for developing research contracts/grants and future revenue streams.
The goal is to conclude the study within six months.
https://www.accesswire.com/753622/Halberd-Pre...l-Approved
Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month's End
JACKSON CENTER, PA / ACCESSWIRE / May 9, 2023 / Halberd Corporation (OTC PINK:HALB) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered. Parameter quantification and preliminary data gathering will begin as early as next week.
Medical literature indicates that a pathophysiologic connection exists between various excess neurotransmitters and certain neurodegenerative diseases. Halberd's study aims to establish positive outcomes through limiting the presence of excess neurotransmitters through its patent-pending triple-action nasal spray containing ingredients to prevent inflammation and swelling, inhibit generation of excess excitatory neurotransmitters, and decrease hypermetabolism.
This nasal spray technology represents an expansion of Halberd's extracorporeal methodology in treating medical conditions through a preventative approach and provides additional intellectual property opportunities, an avenue for developing research contracts/grants and future revenue streams.
The goal is to conclude the study within six months.
(0)
(0)Halberd Corporation (HALB) Stock Research Links
Scroll down for more posts ▼